The M1/M2 macrophage paradigm plays a key role in tumor progression. M1 macrophages
are historically regarded as anti-tumor, while M2-polarized macrophages, commonly …

Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …

Purpose: Recent advances in immunotherapy highlight the antitumor effects of immune
checkpoint inhibition despite a relatively limited subset of patients receiving clinical benefit …

Background–The presence of tumor-infiltrating lymphocytes (TILs) in the tumor
microenvironment is associated with an improved prognosis and a better response to …

Purpose: Despite favorable responses of chimeric antigen receptor (CAR)-engineered T-cell
therapy in patients with hematologic malignancies, the outcome has been far from …

Outcomes for patients with melanoma have improved over the past decade as a result of the
development and FDA approval of immunotherapies targeting cytotoxic T lymphocyte …

Liver metastases remain a major barrier to successful management of malignant disease,
particularly for cancers of the gastrointestinal tract but also for other malignancies, such as …

Improved cancer prognosis is a central goal for precision health medicine. Though many
models can predict differential survival from data, there is a strong need for sophisticated …

In recent years, multiple strategies for eliciting anti-tumor immunity have been developed in
different clinical studies. Currently, immunotherapy was clinically validated as effective …

In recent years, several studies have presented evidence suggesting a potential role for
metformin in anti-cancer therapy. Preclinical studies have demonstrated several anticancer …